On October 3, 2024 NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production, and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, reported it will participate in Oppenheimer & Co. Inc.’s Targeted Radiopharmaceutical Therapies in Oncology Summit being held in New York City on Tuesday, October 8th, 2024 (Press release, NorthStar Medical Radiostopes, OCT 3, 2024, View Source [SID1234647021]). The meeting, Oppenheimer’s second annual event focused on issues, innovations and trends related to development and use of radiopharmaceuticals for treatment of cancer, will consist of topical panels, company presentations, opportunity for various one-on-one meetings and networking.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Frank Scholz, Ph.D., President and Chief Executive Officer of NorthStar will take part, serving as an expert panelist in the session focused on "Supply Chain Challenges and Controversies – Ac-225 Availability, Pb-212 Logistics, The Last Mile" along with representatives from PharmaLogic, SpectronRx, and Perspective Therapeutics.